ClinicalTrials.gg
CompletedNCT00383890Updated Jul 24, 2015

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

A Phase 3 interventional study of Dexmedetomidine HCL Injection and Placebo in Awake Fiberoptic Intubation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.

Read the detailed description

An awake fiberoptic intubation is indicated for any patient with an anticipated difficult airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining spontaneous breathing, hemodynamic stability, and the patient's comfort. The term "awake" fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations performed under general anesthesia. Although patients may be sedated for "awake" fiberoptic intubation, they need to be responsive and capable of maintaining their own airway without assistance. Vital components of a successful awake fiberoptic intubation include an anesthesiologist experienced in this technique, adequate topicalization of the airway, and a sedated yet cooperative subject.

Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia during awake fiberoptic intubations.

Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by decreasing sympathetic activity and the level of arousal. Further more, dexmedetomidine has been found to facilitate a decrease in salivary secretion, a desirable effect during fiberoptic intubations.

An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic intubation because of a potentially difficult airway will be randomized prior to intubation at approximately 18 investigative sites.

02

Conditions studied

  • Awake Fiberoptic Intubation

Keywords

  • American Society of Anesthesiologists (ASA)
  • Mallampati Score
  • Ramsay Sedation Scale (RSS)
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥18 years of age);
  2. (ASA) score I - IV inclusive;
  3. Male or female. If female, subject is non-lactating and is either:

    1. Not of , defined as for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of : oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
  4. Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway. Subjects must meet at least one of the criteria listed below:

    Criteria for Assessing Difficult Airways

    i. History of difficult intubation

    ii. Anticipated difficult airway

    1. Prominent protruding teeth
    2. Small mouth opening
    3. Narrow mandible
    4. Micrognathia
    5. Macroglossia
    6. Short, muscular neck
    7. Very long neck
    8. Limited neck extension
    9. Congenital airway anomalies
    10. Obesity
    11. Known airway pathology
    12. Known airway
    13. Upper airway obstruction

    iii. Trauma

    1. Face
    2. Upper airway
    3. Cervical spine

    iv. Anticipated difficult mask ventilation

    v. Severe risk of aspiration

    vi. Respiratory failure

    vii. Severe hemodynamic instability

  5. Subject (or subject's legally authorized representative) must voluntarily sign and date the .

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to any experimental drug within 30 days prior to study drug administration;
  2. Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak;
  3. Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment;
  4. Presence of acute alcohol intoxication;
  5. Current (within 14 days of study entry) treatment with an α2-agonist or antagonist;
  6. Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are ;
  7. Subject received an IV or oral (PO) opioid within one hour or intramuscularly within four hours of the start of study drug administration;
  8. Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate \<50 bpm, systolic blood pressure (SBP) \<90 mmHg, or complete heart block unless they have a pacemaker.
  9. Subject has elevated serum glutamic pyruvate aminotransferase/ (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase (SGOT/AST) values of ≥2 times the (ULN).
  10. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min

    Drug: Dexmedetomidine HCL Injection

  • Placebo comparator
    Placebo (PBO)

    Placebo load for 10 min and Placebo maintenance for 15 min

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion

    Sedation levels (Ramsay Sedation Scale \[RSS\] score ≥2 \[Patient is cooperative, oriented and tranquil\])

    Time frame: At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.

Secondary outcomes

  1. Total dose of rescue midazolam required to achieve and/or maintain target sedation levels

    Time frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).

  2. Percentage of subjects requiring additional rescue medications other than midazolam to achieve and/or maintain target sedation levels

    Time frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).

  3. Anesthesiologist assessment of ease of subject care

    Time frame: Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).

  4. Subject recall and satisfaction assessed 24 hours post study drug

    Time frame: At the end of the 24-Hour Follow-Up Period

07

Study locations

17 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • University of Miami Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • University of Illinois Medical Center at Chicago
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • The Mount Sinai School of Medicine
    New York, New York 10029, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210-1228, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103-6296, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • VA North Texas Health Care System
    Dallas, Texas 75216, United States
  • The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • The University of Texas
    Houston, Texas 77030, United States
  • Scott and White Memorial Hospital
    Temple, Texas 76508, United States
  • VA Medical Center
    Milwaukee, Wisconsin 53295, United States
08

References and documents

Publications

  • Bergese SD, Candiotti KA, Bokesch PM, Zura A, Wisemandle W, Bekker AY; AWAKE Study Group. A Phase IIIb, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of dexmedetomidine for sedation during awake fiberoptic intubation. Am J Ther. 2010 Nov-Dec;17(6):586-95. doi: 10.1097/MJT.0b013e3181d69072. PubMed 20535016 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jan 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2006
First posted
Oct 4, 2006
Start
Aug 2006
Primary completionActual
Jan 2007
CompletionActual
Mar 2007
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00383890
Responsible party
Sponsor
First posted
Oct 4, 2006
Start date
Aug 2006
Primary completion
Jan 2007
Completion
Mar 2007
Last update
Jul 24, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion